BioBlast w/e 24 Feb 23: Abbvie in hot water over Humira® pricing, Celltrion's Yuflyma® delays explained, Merck/Moderna mRNA vaccine/ Keytruda treatment, French Court overturns Novartis/Roche €444M cartel fine, Amgen's Amjevita® savings, Genetech new biologics facility, Regeneron new aflibercept product, Amgen's Bekemv® eculizumab

The Financial Times has reported that the Dutch Pharmaceutical Accountability Foundation (PAF), a public interest group, is suing AbbVie for…

Related Keywords

Germany ,United States ,Paris ,France General ,France ,Netherlands ,California ,South Korea ,Canada ,America ,Holland ,French ,Korea ,Dutch ,Roche Genentech ,Amgen Amjevita ,Samsung Bioepis Merck ,Eli Lily ,Amgen Bekemv ,Fresenius Kabi ,Mylan Viatris ,Regeneron Eylea ,Abbvie Humira ,Celltrion Yuflyma ,Novartis Roche ,Alexion Soliris ,Amgen ,Boehringer Ingelheim ,Reuters ,Novartis ,Pfizer ,Astrazeneca ,Eu European Commission ,Paris Court ,Dutch Pharmaceutical Accountability Foundation ,Innovent Biologics Inc ,Financial Times ,Korea Biomedical Review ,Innovent Biologics ,Altos Biologics ,Breakthrough Therapy Designation ,Appel De Paris ,Appeal Court ,Expert Review ,Clinical Immunity ,Latin America ,European Commission ,Law ,Lawyers ,Legal ,Aw Firms ,Aw Updates ,Egal Updates ,Egal Developments ,Aw Developments ,Egal Newsletters ,Egal Current Awareness ,Deals ,Egal Advisers ,Egal Advisors ,Egal Directory ,Australia ,Ealthcare Amp Life Sciences ,